Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2023 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Stock Repurchase Plan

SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
January 05, 2023 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to...
December 02, 2022 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer...
November 21, 2022 13:56 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
November 09, 2022 14:10 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
November 08, 2022 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

Anticipate Rosnilimab, our anti-PD-1 agonist antibody, top-line data in the ongoing AZURE Phase 2 trial in moderate-to-severe alopecia areata in Q1 2023Anticipate ANB032, our anti-BTLA agonist...
October 05, 2022 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus...
September 12, 2022 07:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
August 31, 2022 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpointsImsidolimab was safe and well tolerated with no...
August 08, 2022 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3 2022Top-line data from the ongoing rosnilimab...